Industry partnerships to pioneer new advances in diagnostic testing

DIAGNOSTIC TESTING FOR HEALTHY LIVES
Quality, timely diagnostics are key to achieving health for all. The foundation of treatment and public health decision-making, early diagnosis has been consistently linked to improved health outcomes, as well as providing critical data to inform disease management and surveillance. Despite this fact, diagnostics remain the weakest link in the care cascade. In today’s modern world, critical gaps in the development of – and access to – affordable, fit-for-purpose diagnostic tools undermine progress towards universal health coverage and threaten our ability to respond to health emergencies.

1.1 million premature deaths in low- and middle-income countries (LMICs) could be avoided annually by reducing the diagnostic gap for six priority conditions.*

ABOUT FIND
FIND, seeks to ensure equitable access to reliable diagnosis around the world. We connect countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems.

Established in 2003, FIND works with local, regional and global partners to accelerate the development, production and roll-out of fit-for-purpose tests.

CLOSING THE DIAGNOSTIC GAP
With almost 20 years’ operational experience, we help innovators pioneer transformative solutions and navigate the complexities of product development, validation, and endorsement. We also work with in-country partners to promote and enable key market access, and build diagnostic capacity in LMICs.

Together, we can inspire innovation and drive new progress in diagnostics to address current global health challenges and strengthen health systems for the future.

FIND is co-convenor of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar – along with the Global Fund – and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation.

* Diabetes, hypertension, HIV, and tuberculosis in the overall population, and hepatitis B virus infection and syphilis for pregnant women.

Partnerships are the backbone of our work. Together, we can accelerate product development, bring much-needed transparency to the diagnostic market, and generate new data to inform decision-making at every level. Working hand in hand with researchers, developers, and manufacturers, we provide a combination of bespoke support and open access resources to drive forward solutions from concept and feasibility to validation, manufacturing, and roll-out.

20 YEARS’ OPERATIONAL EXPERIENCE
Expert guidance and support
Established partnership networks
Training and capacity building
Funding and investment

BESPOKE PARTNER SUPPORT
Technology assessment
Development planning
Clinical evaluations
Technology transfers
Roll-out and access

OPEN ACCESS RESOURCES
Product landscaping
Market insights
Biobank services
Target product profiles
Online test directories

**PARTNERSHIPS IN ACTION**

As we work to close the gap in diagnostic testing, we are looking to expand our partnership network. Opportunities to partner with FIND are advertised through an open, transparent, and objective request for proposals process, tendered through our organizational website.

For more information, please contact:
info@finddx.org
www.finddx.org

**FIND 2015–2020 STRATEGY IN NUMBERS**

<table>
<thead>
<tr>
<th>New diagnostic technologies enabled</th>
<th>Multi-disease platforms supported</th>
<th>Target product profiles developed</th>
<th>WHO recommendations supported</th>
<th>Health workers trained</th>
<th>Laboratories and facilities strengthened</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>4</td>
<td>29</td>
<td>19</td>
<td>&gt;9,400</td>
<td>3,500</td>
</tr>
</tbody>
</table>

**SPOTLIGHTS**

**PIONEERING THE DEVELOPMENT OF TRANSFORMATIVE TECHNOLOGIES**
A game changer in the field of hepatitis C virus (HCV), the upcoming HCV core antigen rapid diagnostic test (RDT) is designed to simplify diagnostic algorithms and enable decentralized point-of-care testing.

**BRINGING LOCAL INNOVATION TO GLOBAL SCALE**
Supported assay development and multi-centre studies to help secure WHO endorsement of Truenat™ – India’s first point-of-care molecular tuberculosis test – and bring it to a global market.

**EXPANDING LOCAL AND GLOBAL MANUFACTURING CAPACITY**
As part of the ACT-Accelerator, FIND supported capacity building and technology transfers in Asia, South America, and Africa to help secure the production and supply of COVID-19 antigen RDTs in LMICs.

**PARTNER WITH US**
As we work to close the gap in diagnostic testing, we are looking to expand our partnership network. Opportunities to partner with FIND are advertised through an open, transparent, and objective request for proposals process, tendered through our organizational website.

Help break new ground in diagnostic testing.

For more information, please contact: info@finddx.org www.finddx.org

**PHOTO CREDITS:** FIND/BEN PHILLIPS/RYAN RUIZ/ESSAY GEREMEW

**SCANNER:** FIND/DIAGNOSIS FOR ALL